ClinicalTrials.gg
CompletedNCT04229316Updated Jun 3, 2024

Safety And Efficacy Assessment of the zLock Facet Fusion System- A Pilot Study

An interventional study of zLOCK Facet Stabilization System in Low Back Pain, sponsored by ZygoFix. Completed at 1 site in Hungary. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-03.

Sponsored by ZygoFix · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Apr 2018, registered Jan 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Low Back Pain with a site in Hungary — 1 open to participants now, 3 under way, 1 of them phase 3. Low Back Pain · Hungary.

Enrollment
10th of 10
24 · median 225
Started
2018
the only one that year
No phase
6 of 14
1 open now
Registered
6th of 14
by date
Lead sponsor
1 of 14
ZygoFix

Among the 14 studies in Low Back Pain with a site in Hungary, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is one of 6 with no phase, and was the 6th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

1 of the 14 studies in Low Back Pain with a site in Hungary is open now. Recruiting first, the newest first:

A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Low Back Pain with a site in Hungary, or all of them as a file.
02

Study summary

ZygoFix has developed a system consisting of zLOCK Facet Fusion System. The zLOCK Facet Fusion System is intended for single level stabilization of a spinal motion segment to promote bonny fusion of the joint. The system is designed for percutaneous deployment. The zLOCK implant is designed to be deployed in the facet joint thereby utilizing the body's natural mechanical structure without adding an external scaffold (see figure below).

The zLOCK implant is inserted into the facet joint space while it adapts to the joint's changing geometry. Stabilization is achieved by firm grip of each joint bone and resisting to any relative motion. The zLOCK implant is placed percutaneously and requires only one incision per side, thereby reducing the invasiveness, procedure duration and shorten the recovery period.

This pilot study was designed in order to assess the safety and effectiveness of the zLOCK system.

03

Conditions studied

  • Low Back Pain

Keywords

  • stabilization, facet arthritis, spondylolisthesis, stenosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is scheduled for spine surgery with at least one of the following:

    When used in adjunct to an intervertebral front cage:

    • Degenerative Spondylolisthesis up to grade 2
    • Mild to Moderate Degenerative disc disease (DDD)
    • Degeneration of the facets - following validating the pain source by facet injection.

    When used stand-alone:

    • Degenerative Spondylolisthesis grade 1-2
    • Moderate to severe Stenosis with listhesis
    • Moderate to severe stenosis without listhesis (in cases that the investigator determines stabilization is required).
    • Degeneration of the facets- following validating the pain source by facet injection.
  2. Claudication due to moderate to severe stenosis (central/ foraminal) as verified by imaging.
  3. 18\< Age \< 75
  4. Weight \< 100Kg
  5. Signed form
  6. At least 3 months of unsuccessful conventional treatments

Exclusion criteria

Exclusion Criteria:

  1. Fusion procedure performed or required in more than one inter-vertebrae space.
  2. Active systemic infection or infection localized to the site of the proposed implantation are to implantation.
  3. Osteoporosis
  4. Absence of posterior spinal elements including the pedicle, pars interarticularis, facet joints, spinous process and the majority of the lamina which make it unstable or not possible to place.
  5. Any entity or conditions that totally preclude the possibility of fusion, i.e., cancer, kidney dialysis, or osteopenia, are relative contraindications.
  6. Obesity ( ≥30)
  7. Foreign body sensitivity
  8. Alcoholism, or drug abuse
  9. Subject with a cardiac pacemaker or other implanted electro medical device
  10. Subject with known condition of drug abuse and/or alcoholism
  11. Women who are either pregnant or nursing at the time of screening (to be verified by test in case of woman of that do not practice medically acceptable methods of )
  12. Concurrent participation in another clinical trial using any drug or device.
  13. Mental disorders.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    zLock Facet Locking Implant System

    Device: zLOCK Facet Stabilization System

Interventions

  • DevicezLOCK Facet Stabilization System

    zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains

06

What researchers measure

Primary outcomes

  1. Safety assessment - no device related reoperation

    The safety of the zLOCK Facet Implant System will be established based on the absence of device related reoperations.

    Time frame: 3 months

Secondary outcomes

  1. Efficacy assessment - achieving facet fusion 12 months post procedure

    The efficacy of using the zLOCK System will be determined by achieving facet fusion 12 months post procedure. Patient is defined "success" if facet fusion is achieved at 12 months post procedure.

    Time frame: 12 months

07

Study locations

1 site
  • Pecs University Hospital
    Pecs, H-7623, Hungary
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in May 2024, 73 months.

Of 56 industry-sponsored interventional studies with no phase under Low Back Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's 73 months is above that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2020
First posted
Jan 18, 2020
StartActual
Apr 12, 2018
Primary completionActual
May 31, 2024
CompletionActual
May 31, 2024
Last update
Jun 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04229316
Lead sponsor
ZygoFix
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Apr 12, 2018
Primary completion
May 31, 2024
Completion
May 31, 2024
Last update
Jun 3, 2024

Study contacts

Hanna Levy, Dr
study director · ZygoFix

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion